CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy

References

• Zhang XY, Guo XF, Zhang SD, et al. Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis. Int J Ophthalmol 2014;7:355–364.
   PubMed Web of Science ®Google Scholar
• Schauwvlieghe AM, Dijkman G, Hooymans JM, et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. The BRAMD Study. Plos One. 2016;11:e0153052. doi: 10.1371/journal.pone.0153052.
   PubMed Web of Science ®Google Scholar
• Dedania VS, Bakri SJ. Sustained elevation of intraocular pressure after intravitreal anti-VEGF agents: what is the evidence? Retina 2015;35:841–858.
   PubMed Web of Science ®Google Scholar
• Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina 2013;33:179–187.
   PubMed Web of Science ®Google Scholar
• Goel M, Picciani RG, Lee RK, et al. Aqueous humor dynamics: a review. Open Ophthalmol J 2010;4:52–59.
   PubMedGoogle Scholar
• Aspelund A, Tammela T, Antila S, et al. The Schlemm’s canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel. J Clin Invest 2014;124:3975–3986.
   PubMed Web of Science ®Google Scholar
• Janssen SF, Gorgels TG, Van Der Spek PJ, et al. In silico analysis of the molecular machinery underlying aqueous humor production: potential implications for glaucoma. J Clin Bioinforma 2013;3:21. doi: 10.1186/2043-9113-3-21.
   PubMedGoogle Scholar
• Šerý O, Janoutová J, Ewerlingová L, et al. CD36 gene polymorphism is associated with Alzheimer’s disease. Biochimie 2017;135:46–53. doi: 10.1016/j.biochi.2017.01.009.
   PubMed Web of Science ®Google Scholar
• Frost S, Guymer R, Aung KZ, et al. Alzheimer`s disease and the early signs of age-related macular degeneration. Curr Alzheimer Res 2016;13:1259–1266.
   PubMed Web of Science ®Google Scholar
• Sundaresan S, Abumrad NA. Dietary lipids inform the gut and brain about meal arrival via CD36-mediated signal transduction. J Nutr 2015;145:2195–2200.
   PubMed Web of Science ®Google Scholar
• Abdoul-Azize S, Selvakumar S, Sadou H, et al. Ca2+ signaling in taste bud cells and spontaneous preference for fat: unresolved roles of CD36 and GPR120. Biochimie 2014;96:8–13.
   PubMed Web of Science ®Google Scholar
• Daoudi H, Plesník J, Sayed A, et al. Oral fat sensing and CD36 gene polymorphism in algerian lean and obese teenagers. Nutrients 2015;7:9096–9104.
   PubMed Web of Science ®Google Scholar
• Mrizak I, Šerý O, Plesnik J. The A allele of cluster of differentiation 36 (CD36) SNP 1761667 associates with decreased lipid taste perception in obese Tunisian women. Brit J Nutr 2015;113:1330–1337.
   PubMed Web of Science ®Google Scholar
• Ozdener MH, Subramaniam S, Sundaresan S, et al. CD36- and GPR120-mediated Ca2+ signaling in human taste bud cells mediates differential responses to fatty acids and is altered in obese mice. Gastroenterology 2014;146:995–1005.
   PubMed Web of Science ®Google Scholar
• Sayed A, Šerý O, Plesnik J, et al. CD36 AA genotype is associated with decreased lipid taste perception in young obese, but not lean, children. Int J Obes (Lond) 2015;39:920–924.
   PubMed Web of Science ®Google Scholar
• Šerý O, Povová J, Míšek I, et al. Molecular mechanisms of neuropathological changes in Alzheimer’s disease: a review. Folia Neuropathol 2013;51:1–9.
   PubMed Web of Science ®Google Scholar
• Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2009;2:re3.
   PubMed Web of Science ®Google Scholar
• Gilbertson TA, Khan NA. Cell signaling mechanisms of oro-gustatory detection of dietary fat: advances and hallenges. Prog Lipid Res 2014;53:82–92.
   PubMed Web of Science ®Google Scholar
• Housset M, Sennlaub F. Thrombospondin-1 and pathogenesis of age-related macular degeneration. J Ocul Pharmacol Ther 2015;31:406–412.
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Jr VG, Rhee DJ. Matricellular proteins in the trabecular meshwork: review and update. J Ocul Pharmacol Ther 2014;30:447–463.
   PubMed Web of Science ®Google Scholar
• Chu LY, Ramakrishnan DP, Silverstein RL. Thrombospondin-1 modulates VEGF signaling via CD36 by recruiting SHP-1 to VEGFR2 complex in microvascular endothelial cells. Blood 2013;122:1822–1832.
   PubMed Web of Science ®Google Scholar
• Freund KB, Hoang QV, Saroj N, et al. Intraocular pressure in patients with age-related macular degeneration receiving intravitreal aflibercept or ranibizumab. Ophthalmology 2015;122:1802–1810.
   PubMed Web of Science ®Google Scholar
• Kiddee W, Montriwet M. Intraocular pressure changes in non-glaucomatous patients receiving intravitreal anti-vascular endothelial growth factor agents. Plos One 2015;10:e0137833.
   PubMed Web of Science ®Google Scholar
• Rac ME, Safranow K, Rac M, et al. CD36 gene is associated with thickness of atheromatous plaque and ankle-brachial index in patients with early coronary artery disease. Kardiol Pol 2012;70:918–923.
   PubMed Web of Science ®Google Scholar
• Love-Gregory L, Abumrad NA. CD36 genetics and the metabolic complications of obesity. Curr Opin Clin Nutr Metab Care 2011;14:527–534. doi: 10.1097/MCO.
   PubMed Web of Science ®Google Scholar
• Mwaikambo BR, Yang C, Ong H, et al. Emerging roles for the CD36 scavenger receptor as a potential therapeutic target for corneal neovascularization. Endocrin Metab Immune Disord Drug Targets 2008;8:255–272.
   PubMedGoogle Scholar
• Schöllhorn L, Bock F, Cursiefen C. Thrombospondin-1 as a regulator of corneal inflammation and lymphangiogenesis: effects on dry eye disease and corneal graft immunology. J Ocul Pharmacol Ther 2015;31:376–385.
   PubMed Web of Science ®Google Scholar
• Mwaikambo BR, Sennlaub F, Ong H, et al. Genetic ablation of CD36 induces age-related corneal neovascularization. Cornea 2008;27:1037–1041.
   PubMed Web of Science ®Google Scholar
• Resovi A, Pinessi D, Chiorino G, et al. Current understanding of the thrombospondin-1 interactome. Matrix Biol 2014;37:83–91.
   PubMed Web of Science ®Google Scholar
• Cursiefen C, Maruyama K, Bock F, et al. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J Exp Med 2011;208:1083–1092.
   PubMed Web of Science ®Google Scholar
• Popescu V, Pricopie S, Totir M, et al. Clinical use of bevacizumab in treating refractory glaucoma. J Med Life 2015;8:8–12.
   PubMedGoogle Scholar
• Karpinich NO, Caron KM. Schlemm’s canal: more than meets the eye, lymphatics in disguise. J Clin Invest 2014;124:3701–3703.
   PubMed Web of Science ®Google Scholar
• Andrijević-Derk B, Vatavuk Z, Bencić G, et al. Intravitreal bevacizumab for neovascular glaucoma. Acta Clin Croat 2008;47:175–179.
   PubMed Web of Science ®Google Scholar
• Stintzing S. Management of colorectal cancer. F1000Prime Rep 2014;6:108. doi: 10.12703/P6-108.
   Google Scholar
• McMonnies CW. The importance of and potential for continuous monitoring of intraocular pressure. Clin Exp Optom 2016; doi: 10.1111/cxo.12497.
   Web of Science ®Google Scholar
• Solomon SD, Lindsley K, Vedula SS, et al. Antivascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014;8:CD005139. doi: 10.1002/14651858.CD00139.pub3.
   PubMed Web of Science ®Google Scholar